ID   BAZ1A_HUMAN             Reviewed;        1556 AA.
AC   Q9NRL2; Q9NZ15; Q9P065; Q9UIG1; Q9Y3V3;
DT   30-AUG-2002, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   12-OCT-2022, entry version 208.
DE   RecName: Full=Bromodomain adjacent to zinc finger domain protein 1A;
DE   AltName: Full=ATP-dependent chromatin-remodeling protein;
DE   AltName: Full=ATP-utilizing chromatin assembly and remodeling factor 1;
DE            Short=hACF1;
DE   AltName: Full=CHRAC subunit ACF1;
DE   AltName: Full=Williams syndrome transcription factor-related chromatin-remodeling factor 180;
DE            Short=WCRF180;
DE   AltName: Full=hWALp1;
GN   Name=BAZ1A; Synonyms=ACF1, WCRF180; ORFNames=HSPC317;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), IDENTIFICATION BY MASS
RP   SPECTROMETRY, IDENTIFICATION IN THE CHRAC COMPLEX, AND VARIANT LYS-1366.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10880450; DOI=10.1093/emboj/19.13.3377;
RA   Poot R.A., Dellaire G., Huelsmann B.B., Grimaldi M.A., Corona D.F.V.,
RA   Becker P.B., Bickmore W.A., Varga-Weisz P.D.;
RT   "HuCHRAC, a human ISWI chromatin remodelling complex contains hACF1 and two
RT   novel histone-fold proteins.";
RL   EMBO J. 19:3377-3387(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=10655480; DOI=10.1073/pnas.97.3.1038;
RA   Bochar D.A., Savard J., Wang W., Lafleur D.W., Moore P., Cote J.,
RA   Shiekhattar R.;
RT   "A family of chromatin remodeling factors related to Williams syndrome
RT   transcription factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:1038-1043(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=10662543; DOI=10.1006/geno.1999.6071;
RA   Jones M.H., Hamana N., Nezu J., Shimane M.;
RT   "A novel family of bromodomain genes.";
RL   Genomics 63:40-45(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-540 (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RA   Ye M., Zhang Q.-H., Zhou J., Shen Y., Wu X.-Y., Guan Z.Q., Wang L.,
RA   Fan H.-Y., Mao Y.-F., Dai M., Huang Q.-H., Chen S.-J., Chen Z.;
RT   "Human partial CDS from CD34+ stem cells.";
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 746-1556 (ISOFORM 1), AND VARIANT
RP   LYS-1366.
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   IDENTIFICATION IN THE ACF-5 ISWI CHROMATIN REMODELING COMPLEX, AND
RP   INTERACTION WITH SMARCA5.
RX   PubMed=12198550; DOI=10.1038/nature01024;
RA   Hakimi M.-A., Bochar D.A., Schmiesing J.A., Dong Y., Barak O.G.,
RA   Speicher D.W., Yokomori K., Shiekhattar R.;
RT   "A chromatin remodelling complex that loads cohesin onto human
RT   chromosomes.";
RL   Nature 418:994-998(2002).
RN   [9]
RP   FUNCTION, IDENTIFICATION IN THE CHRAC ISWI CHROMATIN REMODELING COMPLEX,
RP   INTERACTION WITH SMARCA5; CHRAC1 AND POLE3, AND MUTAGENESIS OF
RP   667-ILE--LEU-933.
RX   PubMed=12434153; DOI=10.1038/ng1046;
RA   Collins N., Poot R.A., Kukimoto I., Garcia-Jimenez C., Dellaire G.,
RA   Varga-Weisz P.D.;
RT   "An ACF1-ISWI chromatin-remodeling complex is required for DNA replication
RT   through heterochromatin.";
RL   Nat. Genet. 32:627-632(2002).
RN   [10]
RP   FUNCTION, IDENTIFICATION IN THE CHRAC ISWI CHROMATIN REMODELING COMPLEX,
RP   INTERACTION WITH SMARCA5; POLE3 AND CHRAC1, AND MUTAGENESIS OF
RP   1-MET--ASN-128.
RX   PubMed=14759371; DOI=10.1016/s1097-2765(03)00523-9;
RA   Kukimoto I., Elderkin S., Grimaldi M., Oelgeschlager T., Varga-Weisz P.D.;
RT   "The histone-fold protein complex CHRAC-15/17 enhances nucleosome sliding
RT   and assembly mediated by ACF.";
RL   Mol. Cell 13:265-277(2004).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1413 AND SER-1417, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   FUNCTION.
RX   PubMed=17099699; DOI=10.1038/nsmb1170;
RA   Yang J.G., Madrid T.S., Sevastopoulos E., Narlikar G.J.;
RT   "The chromatin-remodeling enzyme ACF is an ATP-dependent DNA length sensor
RT   that regulates nucleosome spacing.";
RL   Nat. Struct. Mol. Biol. 13:1078-1083(2006).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH NCOR1.
RX   PubMed=17519354; DOI=10.1210/me.2007-0095;
RA   Ewing A.K., Attner M., Chakravarti D.;
RT   "Novel regulatory role for human Acf1 in transcriptional repression of
RT   vitamin D3 receptor-regulated genes.";
RL   Mol. Endocrinol. 21:1791-1806(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1402; SER-1413 AND SER-1417,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-270; SER-702 AND SER-960, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-270; SER-1371 AND SER-1402,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-731; SER-1281; SER-1339 AND
RP   SER-1413, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-731; SER-961; SER-1281;
RP   SER-1320; SER-1339; SER-1353; SER-1363; SER-1413; SER-1417 AND THR-1547,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   FUNCTION, IDENTIFICATION IN THE ACF-1 ISWI CHROMATIN REMODELING COMPLEX,
RP   IDENTIFICATION IN THE ACF-5 ISWI CHROMATIN REMODELING COMPLEX, AND
RP   INTERACTION WITH SMARCA1 AND SMARCA5.
RX   PubMed=28801535; DOI=10.15252/embr.201744011;
RA   Oppikofer M., Bai T., Gan Y., Haley B., Liu P., Sandoval W., Ciferri C.,
RA   Cochran A.G.;
RT   "Expansion of the ISWI chromatin remodeler family with new active
RT   complexes.";
RL   EMBO Rep. 18:1697-1706(2017).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-952, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Regulatory subunit of the ATP-dependent ACF-1 and ACF-5 ISWI
CC       chromatin remodeling complexes, which form ordered nucleosome arrays on
CC       chromatin and slide edge- and center-positioned histone octamers away
CC       from their original location on the DNA template to facilitate access
CC       to DNA during DNA-templated processes such as DNA replication,
CC       transcription, and repair (PubMed:17099699, PubMed:28801535). Both
CC       complexes regulate the spacing of nucleosomes along the chromatin and
CC       have the ability to slide mononucleosomes to the center of a DNA
CC       template in an ATP-dependent manner (PubMed:14759371, PubMed:17099699,
CC       PubMed:28801535). The ACF-1 ISWI chromatin remodeling complex has a
CC       lower ATP hydrolysis rate than the ACF-5 ISWI chromatin remodeling
CC       complex (PubMed:28801535). Has a role in sensing the length of DNA
CC       which flank nucleosomes, which modulates the nucleosome spacing
CC       activity of the ACF-5 ISWI chromatin remodeling complex
CC       (PubMed:17099699). Involved in DNA replication and together with
CC       SMARCA5/SNF2H is required for replication of pericentric
CC       heterochromatin in S-phase (PubMed:12434153). May have a role in
CC       nuclear receptor-mediated transcription repression (PubMed:17519354).
CC       {ECO:0000269|PubMed:12434153, ECO:0000269|PubMed:14759371,
CC       ECO:0000269|PubMed:17099699, ECO:0000269|PubMed:17519354,
CC       ECO:0000269|PubMed:28801535}.
CC   -!- SUBUNIT: Component of the ACF-1 ISWI chromatin remodeling complex at
CC       least composed of SMARCA1 and BAZ1A, which regulates the spacing of
CC       histone octamers on the DNA template to facilitate access to DNA
CC       (PubMed:28801535). Within the ACF-1 ISWI chromatin remodeling complex
CC       interacts with SMARCA1; the interaction is direct (PubMed:28801535).
CC       Component of the ACF-5 ISWI chromatin remodeling complex (also called
CC       the ACF complex) at least composed of BAZ1A and SMARCA5/SNF2H, which
CC       regulates the spacing of histone octamers on the DNA template to
CC       facilitate access to DNA (PubMed:10880450, PubMed:12198550,
CC       PubMed:28801535). Within the ACF-5 ISWI chromatin remodeling complex
CC       interacts with SMARCA5/SNF2H; the interaction is direct
CC       (PubMed:10880450, PubMed:12198550, PubMed:28801535). Component of the
CC       CHRAC ISWI chromatin remodeling complex at least composed of
CC       SMARCA5/SNF2H, BAZ1A/ACF1, CHRAC1 and POLE3; the complex preferentially
CC       binds DNA through the CHRAC1-POLE3 heterodimer and possesses ATP-
CC       dependent nucleosome-remodeling activity (PubMed:10880450,
CC       PubMed:12434153, PubMed:14759371). Within the complex interacts (via N-
CC       terminus) with POLE3-CHRAC1 heterodimer; the interaction is direct and
CC       is required for the complex to preferentially bind to DNA
CC       (PubMed:10880450, PubMed:12434153, PubMed:14759371). Within the complex
CC       interacts with SMARCA5/SNF2H; the interaction is direct and promotes
CC       the interaction with the POLE3-CHRAC1 heterodimer (PubMed:10880450,
CC       PubMed:12434153, PubMed:14759371). Interacts with NCOR1 (via its RD1
CC       domain); the interaction corepresses a number of NCOR1-regulated genes
CC       (PubMed:17519354). {ECO:0000269|PubMed:10880450,
CC       ECO:0000269|PubMed:12198550, ECO:0000269|PubMed:12434153,
CC       ECO:0000269|PubMed:14759371, ECO:0000269|PubMed:17519354,
CC       ECO:0000269|PubMed:28801535}.
CC   -!- INTERACTION:
CC       Q9NRL2; P42858: HTT; NbExp=4; IntAct=EBI-927511, EBI-466029;
CC       Q9NRL2; O60264: SMARCA5; NbExp=3; IntAct=EBI-927511, EBI-352588;
CC       Q9NRL2; O95365: ZBTB7A; NbExp=2; IntAct=EBI-927511, EBI-2795384;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Note=May target the CHRAC complex to
CC       heterochromatin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NRL2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NRL2-2; Sequence=VSP_000551;
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis and at low or
CC       undetectable levels in other tissues analyzed.
CC   -!- MISCELLANEOUS: Stimulated by double-stranded DNA and nucleosomal DNA.
CC   -!- SIMILARITY: Belongs to the WAL family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF28995.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF213467; AAF70601.1; -; mRNA.
DR   EMBL; AF221130; AAF32366.1; -; mRNA.
DR   EMBL; AB032252; BAA89209.1; -; mRNA.
DR   EMBL; AL121603; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355885; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471078; EAW65900.1; -; Genomic_DNA.
DR   EMBL; AF161435; AAF28995.1; ALT_FRAME; mRNA.
DR   EMBL; AL050089; CAB43261.1; -; mRNA.
DR   CCDS; CCDS41943.1; -. [Q9NRL2-2]
DR   CCDS; CCDS9651.1; -. [Q9NRL2-1]
DR   PIR; T08738; T08738.
DR   RefSeq; NP_038476.2; NM_013448.2. [Q9NRL2-1]
DR   RefSeq; NP_872589.1; NM_182648.1. [Q9NRL2-2]
DR   PDB; 5UIY; X-ray; 1.69 A; A/B/C/D=1425-1538.
DR   PDBsum; 5UIY; -.
DR   AlphaFoldDB; Q9NRL2; -.
DR   SMR; Q9NRL2; -.
DR   BioGRID; 116347; 109.
DR   ComplexPortal; CPX-434; ACF chromatin remodeling complex.
DR   ComplexPortal; CPX-785; CHRAC chromatin remodeling complex.
DR   CORUM; Q9NRL2; -.
DR   DIP; DIP-36071N; -.
DR   IntAct; Q9NRL2; 45.
DR   MINT; Q9NRL2; -.
DR   STRING; 9606.ENSP00000353458; -.
DR   BindingDB; Q9NRL2; -.
DR   ChEMBL; CHEMBL4105737; -.
DR   iPTMnet; Q9NRL2; -.
DR   MetOSite; Q9NRL2; -.
DR   PhosphoSitePlus; Q9NRL2; -.
DR   SwissPalm; Q9NRL2; -.
DR   BioMuta; BAZ1A; -.
DR   DMDM; 116241266; -.
DR   EPD; Q9NRL2; -.
DR   jPOST; Q9NRL2; -.
DR   MassIVE; Q9NRL2; -.
DR   MaxQB; Q9NRL2; -.
DR   PaxDb; Q9NRL2; -.
DR   PeptideAtlas; Q9NRL2; -.
DR   PRIDE; Q9NRL2; -.
DR   ProteomicsDB; 82383; -. [Q9NRL2-1]
DR   ProteomicsDB; 82384; -. [Q9NRL2-2]
DR   Antibodypedia; 113; 137 antibodies from 24 providers.
DR   DNASU; 11177; -.
DR   Ensembl; ENST00000358716.8; ENSP00000351555.4; ENSG00000198604.11. [Q9NRL2-2]
DR   Ensembl; ENST00000360310.6; ENSP00000353458.1; ENSG00000198604.11. [Q9NRL2-1]
DR   Ensembl; ENST00000382422.6; ENSP00000371859.2; ENSG00000198604.11. [Q9NRL2-1]
DR   GeneID; 11177; -.
DR   KEGG; hsa:11177; -.
DR   MANE-Select; ENST00000360310.6; ENSP00000353458.1; NM_013448.3; NP_038476.2.
DR   UCSC; uc001wsk.4; human. [Q9NRL2-1]
DR   CTD; 11177; -.
DR   DisGeNET; 11177; -.
DR   GeneCards; BAZ1A; -.
DR   HGNC; HGNC:960; BAZ1A.
DR   HPA; ENSG00000198604; Tissue enhanced (bone).
DR   MIM; 605680; gene.
DR   neXtProt; NX_Q9NRL2; -.
DR   OpenTargets; ENSG00000198604; -.
DR   PharmGKB; PA25270; -.
DR   VEuPathDB; HostDB:ENSG00000198604; -.
DR   eggNOG; KOG1245; Eukaryota.
DR   GeneTree; ENSGT00940000158135; -.
DR   HOGENOM; CLU_002479_1_0_1; -.
DR   InParanoid; Q9NRL2; -.
DR   OMA; CEATGKD; -.
DR   OrthoDB; 858930at2759; -.
DR   PhylomeDB; Q9NRL2; -.
DR   TreeFam; TF316326; -.
DR   PathwayCommons; Q9NRL2; -.
DR   SignaLink; Q9NRL2; -.
DR   BioGRID-ORCS; 11177; 21 hits in 1101 CRISPR screens.
DR   ChiTaRS; BAZ1A; human.
DR   GenomeRNAi; 11177; -.
DR   Pharos; Q9NRL2; Tbio.
DR   PRO; PR:Q9NRL2; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q9NRL2; protein.
DR   Bgee; ENSG00000198604; Expressed in sperm and 194 other tissues.
DR   ExpressionAtlas; Q9NRL2; baseline and differential.
DR   Genevisible; Q9NRL2; HS.
DR   GO; GO:0016590; C:ACF complex; IPI:ComplexPortal.
DR   GO; GO:0008623; C:CHRAC; IDA:UniProtKB.
DR   GO; GO:0000228; C:nuclear chromosome; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:ComplexPortal.
DR   GO; GO:0005721; C:pericentric heterochromatin; IC:ComplexPortal.
DR   GO; GO:0003677; F:DNA binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:ComplexPortal.
DR   GO; GO:0006261; P:DNA-templated DNA replication; IDA:UniProtKB.
DR   GO; GO:0006334; P:nucleosome assembly; IDA:ComplexPortal.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:ComplexPortal.
DR   GO; GO:0006275; P:regulation of DNA replication; IMP:ComplexPortal.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central.
DR   GO; GO:0031445; P:regulation of heterochromatin assembly; IBA:GO_Central.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; NAS:BHF-UCL.
DR   CDD; cd05504; Bromo_Acf1_like; 1.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR037325; Acf1_Bromo.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR018501; DDT_dom.
DR   InterPro; IPR028942; WHIM1_dom.
DR   InterPro; IPR028941; WHIM2_dom.
DR   InterPro; IPR013136; WSTF_Acf1_Cbp146.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF02791; DDT; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF10537; WAC_Acf1_DNA_bd; 1.
DR   Pfam; PF15612; WHIM1; 1.
DR   Pfam; PF15613; WSD; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00571; DDT; 1.
DR   SMART; SM00249; PHD; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50827; DDT; 1.
DR   PROSITE; PS51136; WAC; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Bromodomain; Coiled coil;
KW   Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..1556
FT                   /note="Bromodomain adjacent to zinc finger domain protein
FT                   1A"
FT                   /id="PRO_0000211167"
FT   DOMAIN          22..128
FT                   /note="WAC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00475"
FT   DOMAIN          422..487
FT                   /note="DDT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00063"
FT   DOMAIN          1446..1516
FT                   /note="Bromo"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   ZN_FING         1148..1198
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          1..133
FT                   /note="Required for interaction with NCOR1"
FT                   /evidence="ECO:0000269|PubMed:17519354"
FT   REGION          1..128
FT                   /note="Required for interaction with the CHRAC1-POLE3
FT                   heterodimer. Required for interaction with the CHRAC1-POLE3
FT                   heterodimer"
FT                   /evidence="ECO:0000269|PubMed:14759371"
FT   REGION          662..754
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          667..933
FT                   /note="Required for interaction with SMARCA5 and formation
FT                   of the CHRAC ISWI chromatin remodeling complex"
FT                   /evidence="ECO:0000269|PubMed:12434153"
FT   REGION          841..877
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          941..966
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1202..1376
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1399..1431
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          306..397
FT                   /evidence="ECO:0000255"
FT   COILED          634..709
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        662..704
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        711..725
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        841..876
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        949..966
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1202..1216
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1217..1255
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1274..1340
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         270
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         702
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         731
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         960
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88379"
FT   MOD_RES         961
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1320
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1339
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88379"
FT   MOD_RES         1353
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88379"
FT   MOD_RES         1363
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1371
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         1402
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         1413
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1417
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1547
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        952
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         504..535
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10655480"
FT                   /id="VSP_000551"
FT   VARIANT         344
FT                   /note="D -> E (in dbSNP:rs1133285)"
FT                   /id="VAR_028049"
FT   VARIANT         1366
FT                   /note="N -> K (in dbSNP:rs1044140)"
FT                   /evidence="ECO:0000269|PubMed:10880450,
FT                   ECO:0000269|PubMed:17974005"
FT                   /id="VAR_048423"
FT   MUTAGEN         1..128
FT                   /note="Missing: Abolishes interaction with the CHRAC1-POLE3
FT                   heterodimer."
FT                   /evidence="ECO:0000269|PubMed:14759371"
FT   MUTAGEN         667..933
FT                   /note="Missing: Abolishes interaction with SMARCA5/SNF2H,
FT                   and abolishes the formation of the CHRACISWI chromatin
FT                   remodeling complex."
FT                   /evidence="ECO:0000269|PubMed:12434153"
FT   CONFLICT        135
FT                   /note="R -> T (in Ref. 3; BAA89209)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        236
FT                   /note="D -> E (in Ref. 3; BAA89209)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        494
FT                   /note="K -> Q (in Ref. 6; AAF28995)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        503..508
FT                   /note="KDLTEA -> QDFTEP (in Ref. 6; AAF28995)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        525
FT                   /note="S -> P (in Ref. 6; AAF28995)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        536..540
FT                   /note="GCSLK -> AALKF (in Ref. 6; AAF28995)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        551
FT                   /note="E -> D (in Ref. 1; AAF70601)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        730
FT                   /note="V -> F (in Ref. 3; BAA89209)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        769
FT                   /note="P -> L (in Ref. 3; BAA89209)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1201
FT                   /note="S -> C (in Ref. 3; BAA89209)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1206
FT                   /note="S -> F (in Ref. 3; BAA89209)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1409
FT                   /note="R -> K (in Ref. 1; AAF70601 and 7; CAB43261)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1436..1447
FT                   /evidence="ECO:0007829|PDB:5UIY"
FT   HELIX           1449..1454
FT                   /evidence="ECO:0007829|PDB:5UIY"
FT   TURN            1460..1462
FT                   /evidence="ECO:0007829|PDB:5UIY"
FT   HELIX           1466..1469
FT                   /evidence="ECO:0007829|PDB:5UIY"
FT   HELIX           1476..1484
FT                   /evidence="ECO:0007829|PDB:5UIY"
FT   HELIX           1491..1508
FT                   /evidence="ECO:0007829|PDB:5UIY"
FT   HELIX           1514..1532
FT                   /evidence="ECO:0007829|PDB:5UIY"
SQ   SEQUENCE   1556 AA;  178702 MW;  4D78B9A8ADBF715B CRC64;
     MPLLHRKPFV RQKPPADLRP DEEVFYCKVT NEIFRHYDDF FERTILCNSL VWSCAVTGRP
     GLTYQEALES EKKARQNLQS FPEPLIIPVL YLTSLTHRSR LHEICDDIFA YVKDRYFVEE
     TVEVIRNNGA RLQCRILEVL PPSHQNGFAN GHVNSVDGET IIISDSDDSE TQSCSFQNGK
     KKDAIDPLLF KYKVQPTKKE LHESAIVKAT QISRRKHLFS RDKLKLFLKQ HCEPQDGVIK
     IKASSLSTYK IAEQDFSYFF PDDPPTFIFS PANRRRGRPP KRIHISQEDN VANKQTLASY
     RSKATKERDK LLKQEEMKSL AFEKAKLKRE KADALEAKKK EKEDKEKKRE ELKKIVEEER
     LKKKEEKERL KVEREKEREK LREEKRKYVE YLKQWSKPRE DMECDDLKEL PEPTPVKTRL
     PPEIFGDALM VLEFLNAFGE LFDLQDEFPD GVTLEVLEEA LVGNDSEGPL CELLFFFLTA
     IFQAIAEEEE EVAKEQLTDA DTKDLTEALD EDADPTKSAL SAVASLAAAW PQLHQGCSLK
     SLDLDSCTLS EILRLHILAS GADVTSANAK YRYQKRGGFD ATDDACMELR LSNPSLVKKL
     SSTSVYDLTP GEKMKILHAL CGKLLTLVST RDFIEDYVDI LRQAKQEFRE LKAEQHRKER
     EEAAARIRKR KEEKLKEQEQ KMKEKQEKLK EDEQRNSTAD ISIGEEERED FDTSIESKDT
     EQKELDQDMV TEDEDDPGSH KRGRRGKRGQ NGFKEFTRQE QINCVTREPL TADEEEALKQ
     EHQRKEKELL EKIQSAIACT NIFPLGRDRM YRRYWIFPSI PGLFIEEDYS GLTEDMLLPR
     PSSFQNNVQS QDPQVSTKTG EPLMSESTSN IDQGPRDHSV QLPKPVHKPN RWCFYSSCEQ
     LDQLIEALNS RGHRESALKE TLLQEKSRIC AQLARFSEEK FHFSDKPQPD SKPTYSRGRS
     SNAYDPSQMC AEKQLELRLR DFLLDIEDRI YQGTLGAIKV TDRHIWRSAL ESGRYELLSE
     ENKENGIIKT VNEDVEEMEI DEQTKVIVKD RLLGIKTETP STVSTNASTP QSVSSVVHYL
     AMALFQIEQG IERRFLKAPL DASDSGRSYK TVLDRWRESL LSSASLSQVF LHLSTLDRSV
     IWSKSILNAR CKICRKKGDA ENMVLCDGCD RGHHTYCVRP KLKTVPEGDW FCPECRPKQR
     SRRLSSRQRP SLESDEDVED SMGGEDDEVD GDEEEGQSEE EEYEVEQDED DSQEEEEVSL
     PKRGRPQVRL PVKTRGKLSS SFSSRGQQQE PGRYPSRSQQ STPKTTVSSK TGRSLRKINS
     APPTETKSLR IASRSTRHSH GPLQADVFVE LLSPRRKRRG RKSANNTPEN SPNFPNFRVI
     ATKSSEQSRS VNIASKLSLQ ESESKRRCRK RQSPEPSPVT LGRRSSGRQG GVHELSAFEQ
     LVVELVRHDD SWPFLKLVSK IQVPDYYDII KKPIALNIIR EKVNKCEYKL ASEFIDDIEL
     MFSNCFEYNP RNTSEAKAGT RLQAFFHIQA QKLGLHVTPS NVDQVSTPPA AKKSRI
//
